Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 2042 • 2012 ACR/ARHP Annual Meeting
Enhancing Shared Decision-Making in Juvenile Idiopathic Arthritis
Jessica M. Sage¹, Ellen A. Lipstein², William B. Brinkman³, Carole M. Lannon⁴ and Esi M. Morgan DeWitt⁵, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Adolescent Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Division of General and Community Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic disease that requires long-term treatment. Patients and families face multiple treatment decisions over the course of illness…
Abstract Number: 1141 • 2012 ACR/ARHP Annual Meeting
Safety of Celecoxib and Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Juvenile Idiopathic Arthritis
Rachel E. Sobel¹, D. J. Lovell², Hermine Brunner³, Jennifer E. Weiss⁴, Paula W. Morris⁵, Beth S. Gottlieb⁶, Elizabeth C. Chalom⁷, Lawrence K. Jung⁸, Karen Onel⁹, Lisa Petinoit¹⁰, Donald P. Goldsmith¹¹, Staci Abramsky-Risman¹², James P., Young¹³ and Edward H. Giannini¹⁴, ¹Epidemiology, Worldwide Safety Strategy, Pfizer, Inc., New York, NY, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Pediatric Rheumatology, Hackensack Univ Med Ctr, Hackensack, NJ, ⁵Pediatrics, Univ of Arkansas for Med Sci, Little Rock, AR, ⁶Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁷Pediatrics, St. Barnabas Medical Center, Livingston, NJ, ⁸Pediatric Rheumatology, Children's National Medical Center, Washington, DC, ⁹Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ¹⁰Pediatric Rheumatology, 'Specially for Children, Dell Children's Medical Center, Austin, TX, ¹¹Pediatric Rheumaology, St Christopher's Hospital for Children/ Drexel College of Medicine, Philadelphia, PA, ¹²Pfizer Inc, New York, NY, ¹³United BioSource Corporation, Ann Arbor, MI, ¹⁴Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Celecoxib, a selective COX-2 inhibitor, was approved by the FDA for the treatment of the signs and symptoms of JIA in children aged 2-17…
Abstract Number: 2026 • 2012 ACR/ARHP Annual Meeting
High Prevalence of Cervical Spine and Temporomandibular Joint Involvement in Patients with Juvenile Idiopathic Arthritis
Nikolay Tzaribachev¹, Catrin Tzaribachev¹ and Bernd Koos², ¹Pediatric Rheumatology, Center for Rheumatic Diseases, Bad Bramstedt, Germany, ²Clinic of Orthodontics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
Background/Purpose: Detection of involvement of temporomandibular joints (TMJ), which are frequently affected by juvenile idiopathic arthritis (JIA), is only possible on Gadolinium enhanced MRI…
Abstract Number: 1155 • 2012 ACR/ARHP Annual Meeting
A New Measure of Visual Function for Children with Juvenile Idiopathic Arthritis-Associated Uveitis
Sheila T. Angeles-Han¹, Steven Yeh², Courtney McCracken¹, Larry B. Vogler³, Kelly A. Rouster-Stevens⁴, Christine W. Kennedy⁵, Kirsten Jenkins⁶, Matthew Kent³, Scott Lambert⁷, Carolyn Drews-Botsch⁸ and Sampath Prahalad⁹, ¹Emory University School of Medicine, Atlanta, GA, ²Ophthalmology, Emory University School of Medicine, Atlanta, GA, ³Dept of Pediatrics, Emory Univ School of Medicine, Atlanta, GA, ⁴Pediatric Rheumatology, Emory Univ School of Medicine, Atlanta, GA, ⁵Rheumatology Immunology, Emory Children's Center, Atlanta, GA, ⁶Children's Healthcare of Atlanta, Atlanta, GA, ⁷Ophthalmology, Emory Univ School of Medicine, Atlanta, GA, ⁸Epidemiology, Emory University School of Public Health, Atlanta, GA, ⁹Pediatrics, Emory Children's Center, Atlanta, GA
Background/Purpose: Studies on outcomes of children with juvenile idiopathic arthritis-associated uveitis (JIA-U) focus on the clinical ocular exam and physical disability secondary to arthritis. This…
Abstract Number: 2001 • 2012 ACR/ARHP Annual Meeting
Methotrexate and Injectable Tumor Necrosis Factor Alpha Inhibitor Adherence and Persistence in Children with Rheumatic Diseases
Sarah Ringold¹, Shannon Grant², Charmaine Girdish³, Carol A. Wallace⁴ and Sean Sullivan⁵, ¹Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ²Axio Research LLC, Seattle, WA, ³Research, CVS Caremark, Scottsdale, AZ, ⁴Pediatrics, Seattle Childrens Hospital, Seattle, WA, ⁵Health Sciences Building, University of Washington, Seattle, WA
Background/Purpose: Medication adherence and persistence have been demonstrated to have important implications for treatment effectiveness, cost, and safety. Methotrexate is one of the most commonly…
Abstract Number: 1021 • 2012 ACR/ARHP Annual Meeting
Magnetic Resonance Imaging in Follow-up of Clinical Remission in Juvenile Idiopathic Arthritis
Mira van Veenendaal¹, Robert Hemke², Marjolein I. Bos³, Mario Maas⁴, Marion A. J. Van Rossum³ and Taco W. Kuijpers⁵, ¹Departments of Pediatric Rheumatology, Emma Children's Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, ²Departments of Radiology, Academic Medical Center (AMC), Amsterdam, Netherlands, ³Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, ⁴Radiology, Academic Medical Center, Amsterdam, Netherlands, ⁵Pediatric Rheumatology and Immunology, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, Netherlands
Background/Purpose: Despite clinical remission, a substantial proportion of Juvenile Idiopathic Arthritis (JIA) patients will flare after a period of inactive disease. MRI has proven to…
Abstract Number: 2005 • 2012 ACR/ARHP Annual Meeting
Clinical Course and Outcomes of Children with Juvenile Idiopathic Arthritis-Associated Uveitis and Idiopathic Uveitis
Sheila T. Angeles-Han¹, Steven Yeh², Courtney McCracken³, Larry B. Vogler⁴, Kelly A. Rouster-Stevens⁵, Christine W. Kennedy⁶, Matthew Kent⁴, Kirsten Jenkins⁷, Scott Lambert⁸, Carolyn Drews-Botsch⁹ and Sampath Prahalad¹⁰, ¹Pediatrics, Emory Univ School of Medicine, Atlanta, GA, ²Ophthalmology, Emory University School of Medicine, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA, ⁴Dept of Pediatrics, Emory Univ School of Medicine, Atlanta, GA, ⁵Pediatric Rheumatologist, Emory Children's Center, Atlanta, GA, ⁶Rheumatology Immunology, Emory Children's Center, Atlanta, GA, ⁷Children's Healthcare of Atlanta, Atlanta, GA, ⁸Ophthalmology, Emory Univ School of Medicine, Atlanta, GA, ⁹Epidemiology, Emory University School of Public Health, Atlanta, GA, ¹⁰Pediatrics, Emory Children's Center, Atlanta, GA
Background/Purpose: Uveitis can lead to vision loss and blindness. Few studies focus on the outcomes of children with both juvenile idiopathic arthritis-associated uveitis (JIA-U) and…
Abstract Number: 974 • 2012 ACR/ARHP Annual Meeting
Identification of Susceptibility Loci for Inflammatory Arthritis
K. J. A. Steel¹, Anne Hinks², John Bowes³, Joanna Cobb², Edward Flynn⁴, Carl D. Langefeld⁵, Sampath Prahalad⁶, Johannes Peter Haas⁷, John F. Bohnsack⁸, Stephen Guthery⁸, Anne Barton¹, Susan D. Thompson⁹ and Wendy Thomson¹, ¹Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom, ⁵Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁶Pediatrics, Emory Children's Center, Atlanta, GA, ⁷Childrens Hospital, Erlangen, Germany, ⁸Department of Pediatrics,, University of Utah, Salt Lake City, ⁹Department of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: One of the principal findings of genome wide association studies in autoimmune diseases has been the substantial overlap of genetic susceptibility loci identified. This…
Abstract Number: 2007 • 2012 ACR/ARHP Annual Meeting
Radiological Peripheral Involvement At Hands, Feet and Hips in Young Adults with Polyarticular Idiopathic Juvenile Arthritis
Muriel Elhai¹, Ramin Bazeli², Veronique Freire², Antoine Feydy², Andre Kahan³, Chantal Job-Deslandre⁴ and Julien Wipff¹, ¹Rheumatology A, Paris Descartes University, Cochin Hospital, APHP, Paris, France, ²Radiology B, Paris Descartes University, Cochin Hospital, APHP, Paris, France, ³Service de Rhumatologie A, Rheumatology A, Paris Descartes University, Cochin Hospital, APHP, Paris, France, ⁴Service de Rhumatologie, Rheumatology A, Paris Descartes University, Cochin Hospital, APHP, Paris, France
Background/Purpose: Radiographic damage was recently considered to be a feature of poor prognosis in cases of polyarticular juvenile idiopathic arthritis (pJIA). However, most radiographic studies…
Abstract Number: 760 • 2012 ACR/ARHP Annual Meeting
Catch-up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: 2-Year Data From a Phase 3 Clinical Trial
Fabrizio De Benedetti¹, Nicolino Ruperto², Graciela Espada³, Valeria Gerloni⁴, Berit Flato⁵, Gerd Horneff⁶, Barry L. Myones⁷, Karen Onel⁸, James Frane⁹, Andrew Kenwright¹⁰, Terri H. Lipman¹¹, Kamal N. Bharucha⁹, Alberto Martini⁷ and D. J. Lovell¹², ¹Division of Rheumatology, Department of Pediatric Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ²Paediatric Rheumatology International Trials Organisation [PRINTO], Genova, Italy, ³Paediatric Rheumatology International Trials Organisation–IRCCS [PRINTO], Genova, Italy, ⁴Istituto Gaetano Pini, Milan, Italy, ⁵Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁶Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, ⁷Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, ⁸PRCSG, Cincinnati, OH, ⁹Genentech, South San Francisco, CA, ¹⁰Roche, Welwyn Garden City, United Kingdom, ¹¹University of Pennsylvania School of Nursing, Philadelphia, PA, ¹²Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA), characterized by chronic arthritis associated with prominent systemic and laboratory features, also has a significant impact on the growing…
Abstract Number: 2011 • 2012 ACR/ARHP Annual Meeting
ACR Criteria, Providers’ Global Rating of Change and Role of Patient Self-Report in Evaluating Change in Disease Over Time: A Patient Reported Outcomes Measurement Information System Study
Bin Huang¹, Jennifer Farrell², Adam Carle³, Stacey Niehaus³, Hermine Brunner⁴, Alexei A. Grom⁵, Michael Henrickson⁶, Jennifer L. Huggins⁴, D. J. Lovell⁷, Tracy V. Ting⁴ and Esi M. Morgan DeWitt², ¹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH, ²Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵PRCSG, Cincinnati, OH, ⁶MLC 4010, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: As part of a longitudinal study of Juvenile Idiopathic Arthritis (JIA), providers completed clinical outcomes assessments and patients (pt) completed self-report measures at clinic…
Abstract Number: 762 • 2012 ACR/ARHP Annual Meeting
Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis
Yukiko Kimura¹, Jennifer E. Weiss², Kathryn L. Haroldson¹, Tzielan C. Lee³, Marilynn G. Punaro⁴, Sheila K. Feitosa de Oliveira⁵, C. Egla Rabinovich⁶, Meredith P. Riebschleger⁷, Jordi Anton⁸, Peter R. Blier⁹, Valeria Gerloni¹⁰, Melissa M. Hazen¹¹, Elizabeth Kessler¹², Karen Onel¹³, Murray H. Passo¹⁴, Robert M. Rennebohm¹⁵, Carol A. Wallace¹⁶, Patricia Woo¹⁷, Nico M. Wulffraat¹⁸ and CARRAnet Investigators¹⁹, ¹Pediatric Rheumatology, JM Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ³Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁴Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ⁵Pediatric Rheumatology, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ⁷Pediatric Rheumatology & Health Services Research, University of Michigan, Ann Arbor, MI, ⁸Rheumatology, Hospital Sant Joan de Deu, Barcelona, Spain, ⁹Pediatrics, Baystate Children's Hospital, Springfield, MA, ¹⁰Pediatric Rheumatology, Gaetano Pini Chair of Rheum, Milan, Italy, ¹¹Division of Immunology, Boston Children's Hospital, Boston, MA, ¹²Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ¹³Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ¹⁴Pediatrics, Medical University of South Carolina, Charleston, SC, ¹⁵Pediatric Rheumatology, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, ¹⁶Pediatrics, Seattle Childrens Hospital, Seattle, WA, ¹⁷Division of Infection and Immunity, University College London, London, United Kingdom, ¹⁸Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁹Durham
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is characterized by fevers, rash and arthritis, for which IL1 and IL6 inhibitors appear to be effective. Pulmonary artery…
Abstract Number: 2018 • 2012 ACR/ARHP Annual Meeting
Juvenile Idiopathic Arthritis in Adulthood: Evaluation of Disease Activity, Damage and Quality of Life
Alessandra Salmaso¹, Lorenzo Ceri², Serena Capannini², Francesco La Torre³, Maurizio Gattinara⁴, Irene Pontikaki¹, Pier Luigi Meroni⁵, Fernanda Falcini² and Valeria Gerloni¹, ¹Pediatric Rheumatology, G. Pini Institute, Department and Chair of Rheumatology, Milan, Italy, ²Department of Internal Medicine, Rheumatology Section, Transition Clinic, University of Florence, Firenze, Italy, ³DIMIMP-University, Rheumatologic Section, Bari, Italy, ⁴Pediatric Rheumatology, Pediatric Rheumatology, G. Pini Institute, Department and Chair of Rheumatology, Milan, Italy, ⁵Dept. of clinical and community science, Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy
Background/Purpose: : Health outcomes in Juvenile Idiopathic Arthritis (JIA) have been a very active area of research in the past several years. Altogether, the available…
Abstract Number: 475 • 2012 ACR/ARHP Annual Meeting
Immunologic Responsiveness in Patients with Juvenile Idiopathic Arthritis On Methotrexate and Etanercept: 23 Valent Pneumococcal Vaccination
Ankur A. Kamdar¹, Patricia C. Giclas² and Barry L. Myones³, ¹Rheumatology, University of Texas Medical School at Houston, Houston, TX, ²Pediatric Allergy and Immunology, National Jewish Health, Denver, CO, ³Pediatrics, Baylor College of Medicine, Houston, TX
Background/Purpose: There is a paucity of data regarding response to vaccinations in patients with juvenile idiopathic arthritis (JIA) treated with methotrexate (MTX). It is also…
Abstract Number: 2019 • 2012 ACR/ARHP Annual Meeting
A Novel MRI Scoring System for the Evaluation of Early-Stage Disease Activity of the Wrist in Juvenile Idiopathic Arthritis
Charlotte M. Nusman¹, Robert Hemke¹, Taco W. Kuijpers², Eline E. Deurloo¹, Dieneke Schonenberg³, J. Merlijn Van den Berg⁴, Koert M. Dolman⁵, Marion A.J. Van Rossum⁴ and Mario Maas¹, ¹Department of Radiology, Academic Medical Center, Amsterdam, Netherlands, ²Pediatric Rheumatology and Immunology, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, Netherlands, ³Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, ⁴Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital / Academic Medical Center and Reade Institute, Amsterdam, Netherlands, ⁵Pediatric Rheumatology, St. Lucas Andreas Hospital and Reade Institute, Amsterdam, Netherlands
Background/Purpose: Evidence that early therapeutic intervention prevents structural damage in juvenile idiopathic arthritis (JIA) patients requires focus on early-stage disease activity scores. Most outcome measures…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].